EfficientRMT-Net-An Efficient ResNet-50 and Vision Transformers Approach for Classifying Potato Plant Leaf Diseases.

The primary objective of this study is to develop an advanced, automated system for the early detection and classification of leaf diseases in potato plants, which are among the most cultivated vegetable crops worldwide. These diseases, notably early and late blight caused by Alternaria solani and Phytophthora infestans, significantly impact the quantity and quality of global potato production. We hypothesize that the integration of Vision Transformer (ViT) and ResNet-50 architectures in a new model, named EfficientRMT-Net, can effectively and accurately identify various potato leaf diseases. This approach aims to overcome the limitations of traditional methods, which are often labor-intensive, time-consuming, and prone to inaccuracies due to the unpredictability of disease presentation. EfficientRMT-Net leverages the CNN model for distinct feature extraction and employs depth-wise convolution (DWC) to reduce computational demands. A stage block structure is also incorporated to improve scalability and sensitive area detection, enhancing transferability across different datasets. The classification tasks are performed using a global average pooling layer and a fully connected layer. The model was trained, validated, and tested on custom datasets specifically curated for potato leaf disease detection. EfficientRMT-Net's performance was compared with other deep learning and transfer learning techniques to establish its efficacy. Preliminary results show that EfficientRMT-Net achieves an accuracy of 97.65% on a general image dataset and 99.12% on a specialized Potato leaf image dataset, outperforming existing methods. The model demonstrates a high level of proficiency in correctly classifying and identifying potato leaf diseases, even in cases of distorted samples. The EfficientRMT-Net model provides an efficient and accurate solution for classifying potato plant leaf diseases, potentially enabling farmers to enhance crop yield while optimizing resource utilization. This study confirms our hypothesis, showcasing the effectiveness of combining ViT and ResNet-50 architectures in addressing complex agricultural challenges.

Pain Relief Durations of Different Concentrations of Lidocaine in Wide Awake Hand Surgery: A Prospective Randomised Clinical Trial.

OBJECTIVE: This study aims to determine the minimal concentration of lidocaine to provide adequate analgesia in wide awake local anaesthesia no tourniquet (WALANT) hand surgeries comparing 3 dilutions of tumescent lidocaine with epinephrine solution. STUDY DESIGN: A randomised control trial. Place and Duration of the Study: The study was held at the Plastic Surgery Department of Mayo Hospital, Lahore, from September 2020 to March 2021. METHODOLOGY: Inclusion criteria were post-traumatic hand contractures and tendon and nerve injuries. The patients were randomised to 3 groups of 30 each: Group A (0.1% lidocaine), Group B (0.2% lidocaine), and Group C (0.3% lidocaine). The dilution of adrenaline also remained constant at 1:200,000. Pain was measured using the Visual Analogue Scale. The three groups were compared for demographics and the total duration of analgesia in minutes. RESULTS: All groups showed adequate pain relief during surgery with no cases requiring conversion to general anaesthesia. The highest total duration of analgesia was seen in the 0.3% group (805.3±195.2 minutes), followed by the 0.2% group (500.4±87.2 minutes) and 0.1% group (381.3±31.6 minutes) (p<0.05). No patient developed any signs of lidocaine toxicity. A low Lidocaine concentration of 0.1% was effective in providing analgesia during surgery though increasing the lidocaine concentration to 0.3% would result in greater post-operative analgesic time without increasing toxicity. CONCLUSION: Adequate analgesia was recorded with all 3 lidocaine concentrations. The greatest pain-free duration was however observed in the  0.3% lidocaine group. KEY WORDS: Wide awake local anaesthesia no tourniquet (WALANT), Lidocaine concentrations, Hand surgery, Analgesia, Adverse effects.

Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of Withanone using validated UPLC method: An active constituent of neuroprotective herb Ashwagandha.

ETHNOPHARMACOLOGICAL RELEVANCE: Withanone (WN), an active constituent of Withania somnifera commonly called Ashwagandha has remarkable pharmacological responses along with neurological activities. However, for a better understanding of the pharmacokinetic and pharmacodynamic behavior of WN, a comprehensive in-vitro ADME (absorption, distribution, metabolism, and excretion) studies are necessary. AIM OF THE STUDY: A precise, accurate, and sensitive reverse-phase ultra-performance liquid chromatographic method of WN was developed and validated in rat plasma for the first time. The developed method was successfully applied to the in-vitro ADME investigation of WN. MATERIAL AND METHODS: The passive permeability of WN was assayed using PAMPA plates and the plasma protein binding (PPB) was performed using the equilibrium dialysis method. Pooled liver microsomes of rat (RLM) and human (HLM) were used for the microsomal stability, CYP phenotyping, and inhibition studies. CYP phenotyping was evaluated using the specific inhibitors. CYP inhibition study was performed using specific probe substrates along with WN or specific inhibitors. RESULTS: WN was found to be stable in the simulated gastric and intestinal environment and has a high passive permeability at pH 4.0 and 7.0 in PAMPA assay. The PPB of WN at 5 and 20 µg/mL concentrations were found to be high i.e. 82.01 ± 1.44 and 88.02 ± 1.15%, respectively. The in vitro half-life of WN in RLM and HLM was found to be 59.63 ± 2.50 and 68.42 ± 2.19 min, respectively. CYP phenotyping results showed that WN was extensively metabolized by CYP 3A4 and1A2 enzymes in RLM and HLM. However, the results of CYP Inhibition studies showed that none of the CYP isoenzymes were potentially inhibited by WN in RLM and HLM. CONCLUSION: The in vitro results of pH-dependent stability, plasma stability, permeability, PPB, blood partitioning, microsomal stability, CYP phenotyping, and CYP inhibition studies demonstrated that WN could be a better phytochemical for neurological disorders.

Phospholipid complexation of NMITLI118RT+: way to a prudent therapeutic approach for beneficial outcomes in ischemic stroke in rats.

Withania somnifera Dunal (Solanaceae) known as Ashwagandha, a popular plant of Indian origin is known to possess tremedous medicinal potential, often used as anti-inflammatory, anti-platelet, antihypertensive, hypoglycemic, hypolipidemic and adaptogenic candidate. Some of its chemotypes developed by CSIR, India includes NMITLI-101, NMITLI-118, NMITLI-128. In this study the investigators have attempted development of a phytosomal complex of NMITLI118RT + (standardized ethanolic extract of a new chemotype of W. somnifera Dunal.), its pharmaceutical characterization and evaluation of its neuro-protective potential against experimenal stroke in rats in continuation with their previous work in this area. The phytosomal complex (NIMPLC) was prepared by following a cohesive optimization design and was characterized on the basis of solubility, dissolution profile, FT-IR, DSC-TGA analysis, zeta potential, physical stability, forced degradation and photolytic degradation. Results were suggestive of a pharmaceutically acceptable formulation. NIMPLC was taken up further for biological evaluation using the middle cerebral artery occlusion (MCAO) model in rats. It could be demonstrated that the beneficial effects of NMITLI118RT + could be augmented by NIMPLC in 1 h pre and 6 h post treatment as was evident from reduction in MDA levels, increment in GSH levels, reduction in neurological deficit (ND) scores and reduction in infarct size. The study could successfully demonstrate the beneficial effects of NIMPLC in brain function restoration following stroke.

Neuro-protective potential of a vesicular system of a standardized extract of a new chemotype of Withania somnifera Dunal (NMITLI118RT+) against cerebral stroke in rats.

Withania somnifera Dunal is an Indian medicinal plant with significant pharmacological properties, such as adaptogenic, anti-inflammatory, anti-oxidant, anti-platelet, anti-hypertensive, hypoglycemic and hypolipidemic effects. Several chemotypes of W. somnifera include NMITLI-101, NMITLI-118 and NMITLI-128. The present work elaborates the optimization and development of a liposomal delivery system for efficient delivery of NMITLI118RT+ [a standardized ethanolic extract of a new chemotype of W. somnifera Dunal (NMITLI-118) roots] against cerebral stroke in rats. Liposomal systems were prepared using thin-film hydration method and characterized on the basis of size, zeta potential, physical stability, FT-IR, DSC-TGA analysis and surface morphological studies by TEM. NMITLI118RT+ and its formulations (NMITLI118RT+LF) were evaluated for biological activity utilizing middle cerebral artery occlusion model in rats. The Z average of the developed liposomal formulation was about 142.6 ± 0.09 nm with a zeta potential of -31.20 ± 1.0 mV. Results of TEM revealed spherical particles in the range of 200 nm. The entrapment efficiency was found to be 94.603 ± 2%. The formulation was found to be physically stable over a 3-week period. Results were suggestive of the fact that both NMITLI118RT+ and its delivery system possess significant neuroprotective activity in cerebral ischemia. The liposomal system largely exhibits better performance over NMITLI118RT+ precisely in the post-treatment group. The present studies could elucidate the successful development of a delivery system for NMITLI118RT+ and demonstrate their beneficial neuro-protective potential in overcoming and reversing the consequences of I/R injury following stroke.

Stability indicating studies on NMITLI 118RT+ (standardized extract of withania somnifera dunal).

BACKGROUND: Withania somnifera Dunal (Ashwagandha) is an Indian medicinal plant of great medicinal value; used in many clinically proven conditions. NMITLI-118RT+ is a candidate drug under a Council of Scientific and Industrial Research (CSIR) networking project. It is a chemotype of W. somnifera's root extract, which has been used for the present study. OBJECTIVES: The present investigation aims to develop and validate a simple isocratic reverse phase-high performance liquid chromatography (RP-HPLC) system for the detection and estimation of Withanolide A (marker compound) and its analytical application for stability indicating studies on NMITLI-118RT+. MATERIAL AND METHODS: A validated RP-HPLC method for Withanolide A was established on a Waters HPLC system and the same was used on NMITLI-118RT+ for quantification and fingerprinting purposes, and for establishing forced degradation, isothermal stress tests, and drug-excipient testing protocols as per International Conference on Harmonization (ICH) guidelines. RESULTS: A validated method was established, which could detect the marker at a retention time of around 6.3 minutes, with a linearity range of 2-100 µg/mL, by varying the amounts of the said marker, which were estimated in four different batches of NMITLI-118RT+. Photostability as per ICH guidelines suggested a slight loss of the active constituent and maximum degradation was afforded with alkali followed by acid, and then peroxide, in the forced degradation studies. In the drug-excipient studies, the maximum amount of active constituent could be detected in the samples with ethyl cellulose and the least with hydroxy propyl cellulose. CONCLUSION: The method developed here was simple and rapid. The various stability indicating studies carried out in the present investigation would be useful for formulation development and were suggestive of deciding the recommended storage conditions for NMITLI-118RT+.

Mimosa pudica L. (Laajvanti): An overview.

Mimosa pudica L. (Mimosaceae) also referred to as touch me not, live and die, shame plant and humble plant is a prostrate or semi-erect subshrub of tropical America and Australia, also found in India heavily armed with recurved thorns and having sensitive soft grey green leaflets that fold and droop at night or when touched and cooled. These unique bending movements have earned it a status of 'curiosity plant'. It appears to be a promising herbal candidate to undergo further exploration as evident from its pharmacological profile. It majorly possesses antibacterial, antivenom, antifertility, anticonvulsant, antidepressant, aphrodisiac, and various other pharmacological activities. The herb has been used traditionally for ages, in the treatment of urogenital disorders, piles, dysentery, sinus, and also applied on wounds. This work is an attempt to explore and compile the different pharmacognostic aspects of the action plant M. pudica reported till date.